1. A compound of the formula
14
or a pharmaceutically acceptable salt thereof, wherein
the dashed lines represent optional double bonds;
A is nitrogen or CR7;
B is NR1R2, CR1R2R10 C(CR2R11)R1, NHCR1R2R10, OCR1R2R10, SCR1R2R10, CR2R10NHR1, CR2R10R1, CR2R10SR1 or COR2;
J and K are each independently nitrogen or carbon and both J and K are not nitrogens;
D and E are each selected, independently, from nitrogen, CR4, CO, CS, sulfur, oxygen, CR4R6 and NR8;
G is nitrogen or carbon;
the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two CO or CS groups;
R1 is C1-C6 alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, O(C1-C4 alkyl), CF3, C(O)O(C1-C4alkyl), OC(O)(C1-C4 alkyl), OC(O)N(C1-C4 alkyl)(C1-C2 alkyl), NHCO(C1-C4 alkyl), COOH, COO(C1-C4 alkyl), CONH(C1-C4 alkyl), CON(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C4 alkyl), CN, NO2, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2NH(C1-C4 alkyl) and SO2N(C1-C4 alkyl)(C1-C2 alkyl), wherein each of the C1-C4 alkyl groups in the foregoing R1 groups may optionally contain one or two double or triple bonds;
R2 is C1-C12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1-C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C1-C4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C3-C8 cycloalkyl or (C1-C6 alkylene)(C3-C8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C1-C6 alkylene)(C3-C8 cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ2 wherein Z2 is selected from hydrogen, C1-C4 alkyl, benzyl and C1-C4 alkanoyl, and wherein each of the foregoing R2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C1-C4 alkyl, or with one substituent selected from bromo, iodo, C1-C6 alkoxy, OC(O)(C1-C6 alkyl), OC(O)N(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C6 alkyl), amino, NH(C1-C2 alkyl), N(C1-C2 alkyl)(C1-C4 alkyl), N(C1-C4 alkyl)CO(C1-C4 alkyl), NHCO(C1-C4 alkyl), COOH, COO(C1-C4 alkyl), CONH(C1-C4 alkyl), CON(C1-C4 alkyl)(C1-C2 alkyl), SH, CN, NO2, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2NH (C1-C4 alkyl) and SO2N(C1-C4 alkyl)(C1-C2 alkyl);
NR1R2 or CR1R2R10 may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ3 wherein Z3 is hydrogen, C1-C4 alkyl, benzyl or C1-C4 alkanoyl;
R3 is hydrogen, C1-C4 alkyl, O(C1-C4 alkyl), chloro, fluoro, bromo, iodo, (C1-C2 alkylene)O(C1-C2 alkyl), (C1-C2 alkylene)-OH, or S(C1-C4 alkyl);
each R4 is, independently, hydrogen, (C1-C6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C1-C2 alkylene)OH, CF3, CH2SCH3, nitro, O(C1-C4 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C4 alkyl), CO(C1-C alkyl), C(O)H or C(O)O(C1 -C4alkyl);
R6 is hydrogen, methyl or ethyl;
R8 is hydrogen or C1-C4 alkyl;
R5 is phenyl, pyndyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R5 groups is substituted with from one to four substituents R13 wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C1-C6 alkyl and O(C1-C6 alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C1-C4 alkylene)OH, (C1-C4alkylene)O(C1-C2 alkyl), CN, CF3, NO2, NH2, NH(C1-C4 alkyl), N(C1-C2 alkyl)(C1-C. alkyl), OCO(C1-C4 alkyl), (C1-C4 alkylene)O(C1-C4 alkyl), S(C1-C6 alkyl), (Cl -C4 alkylene)S(C1-C4 alkyl), C(O)O(C1-C4 alkyl), C(O)(C1-C4 alkyl), COOH, SO2NH(C1-C4 alkyl), SO2N(C1-C2 alkyl)(C1-C4 alkyl), SO2NH2, NHSO2(C1-C4 alkyl), S(C1-C6 alkyl) and SO2(C1-C6 alkyl), and wherein each of the C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally have one or two double bonds;
R7 is hydrogen, C1-C4 alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, O(C1-C4 alkyl), C(O)(C1-C4 alkyl), C(O)O(C1-C4 alkyl), OCF3, CF3, CH2OH or CH2O(C1-C2 alkyl);
R10 is hydrogen, hydroxy, methoxy or fluoro;
R11 is hydrogen or C1-C4 alkyl; and
with the proviso that: a) when both J and K are carbons and D is CR4 and E is nitrogen, then G can not be nitrogen; (b) when both J and K are carbons and D and G are nitrogens, then E can not be CR4 or CO or CS; (c) when both J and K are carbons and D and E are carbons, then G can not be nitrogen; (d) when G is carbon, it must be double banded to E; and (e) in the ring containing J, K, D, E and G, there can not be two double bonds adjacent to each other;
and the pharmaceutically acceptable salts of such compounds.
2. Compounds according to claim 1 wherein B is NR1R2, NHCHR1R2, OCHR1 R2 and R1 is C1-C6 alkyl, which may optionally be substituted with one fluoro, or C1-C4 alkoxy group and which may optionally contain one double or triple bond; and R2 is C1-C4 alkyl or (C1-C2 alkyl)CO(C1-C2 alkyl) which may optionally contain one double or triple bond.
3. Compounds according to claim 1, wherein B is CHR1R2, NR1R2, NHCHR1R2, OCHR1R21 SCHR1R2; and R1 is C1-C6 alkyl, which may optionally be substituted with one hydroxy, fluoro, CF3, cyclopropyl or C1-C4 alkoxy group and which may optionally contain one double or triple bond; and R2 is benzyl or C1-C6 alkyl, which may optionally contain one double or triple bond, wherein said C1-C6 alkyl and the phenyl moiety of said benzyl may optionally be substituted with one fluoro, hydroxy, CF3, cyclopropyl, C1-C2 alkyl, C1-C2 alkoxy or chloro group.
4. Compounds according to claim 1 wherein R3 is methyl.
5. Compounds according to claim 1 wherein R4, R6, R8, R9, and R12 are hydrogen or methyl.
6. Compounds according to claim 1 wherein R5 is di- or tri-substituted phenyl in which the two or three substitutents are independently selected from C1-C4 alkyl, O(C1-C4 alkyl), (C1-C4 alkylene)O(C1-C4alkyl), CF3, OCF3, CHO, (C1-C4alkylene)OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing (C1-C4) alkyl groups may optionally contain one double or triple bond.
7. Compounds 1 wherein R3 is methyl, ethyl, chloro or methoxy; and each of R4, R6, R8, R9, and R12 is, independently, hydrogen, methyl or ethyl.
8. Compounds wherein R5 is di- or tri-substituted pyridyl, or pyrimidyl in which the two or three substitutents are independently selected from C1-C4 alkyl, O(C1C4 alkyl), (C1-C4 alkylene)O(C1-C, alkyl), CF3, OCF3, CHO, (C1-C4 alkylene)OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing (C1-C4) alkyl groups may optionally contain one double or triple bond.
9. Compounds according to claim 1 wherein A is N, CH or CCH3.
10. Compounds according to claim 1 wherein A is CH, J and K are carbon and D, E, and G are nitrogen.
11. Compounds according to claim 1 wherein J and D are nitrogen, and K and G are carbon, and E is CH, CCH, or CC2H5.
12. Compounds according to claim 1 wherein J and K are carbon, and DEG is OC(CH3)C, 0CHC, SC(CH3)C, SCHC, N(CH3)C(CH3)C, NHC(CH3)C, NHC(CH3CH2)C, N(CH3)CHC, ONC, SNC, N(CH3)NC, OCH2N or SCH2N.
13. A compound according to claim 1 wherein B is CHR1R2, NCHR1R2 or OCHR1R2, and the CHR1R2 group of B is a cyclopentane ring, a tetrahydrofuran ring or a tetrahydrothienyl ring.
14. A compound according to claim 1 wherein the NR1 R2 group of B is a five membered saturated or unsaturated heterocyclic ring.
15. A compound according to claim 14 wherein the NR1R2 is a pyrrolo ring, a pyrrolidino ring, a thiazolidino ring or a morpholino ring.
16. A pharmaceutical composition for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent, depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn’s disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g, porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer’s type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of such disorder, and a pharmaceutically acceptable carrier.
17. A method for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn’s disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Aizheimer’s type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, comprising administering to a subject in need of said treatment an amount of a compound according to claim 1, that is effective in treating such disorder.
18. A method of treating or preventing a disorder or condition, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein in a mammal, comprising administering to said mammal a CRH binding protein inhibiting amount of a compound according to claim 1.
19. A pharmaceutical composition for treating or preventing a disorder or condition, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein in a mammal, comprising a CRH binding protein inhibiting amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
20. A compound according to claim 11 or 12 wherein A is N or CH, R3 is methyl and each R4, R6, R8, R9 and R12 is, independently, hydrogen or methyl.
21. A compound according to claim 20, wherein R5 is di- or tri-substituted phenyl, wherein the two or three substitutents are independently selected from C1-4 alkyl, O(C1-C4 alkyl), (C1-C4 alkylene)O(C1-C4alkyl), CF3, OCF3, CHO, (C1-C4alkylene)OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing (C1-C4) alkyl groups may optionally contain one double or triple bond.
22. A compound of the formula
15
wherein R3is C1-C4 alkyl, R7is hydrogen, methyl, chloro, bromo, COOH or COO(C1-C4 alkyl), T is chloro, bromo, iodo or triflate, R8 is hydrogen or C1-C4 alkyl and R 4 is hydrogen, (C1-C6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C1-C2 alkylene)OH, CF3, CH2SCH3, nitro, O(C1-C4 alkyl), N(Ci-C4 alkyl)(C1-C2 alkyl), S(C1-C4 alkyl), CO(C1-C4 alkyl), C(O)H or C(O)O(C1-C4alkyl).
23. A compound according to claim 1 wherein said compound is:
7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo1,5-apyrimidine;
2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo1,5-apyrimidin-7-yl-(1-ethyl-propyl)-amine;
(1-Ethyl-propyl)-5-methyl-3-(2,4,6trimethyl-phenyl)-pyrazolo1,5-apyrimidin-7-yl-amine;
7-(1-Ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo1,5-apyrimidine;
2,5-Dimethyl-3-(2,4,6trimethyl-phenyl)-pyrazolo1,5-apyrimidin-7-yl-ethyl-propyl-amine;
6-Bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-1,2,3triazolo 4,5-bpyridin-7-yl-(1-ethyl-propyl)-amine;
(1-Ethyl-propyl)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-1,2,3triazolo4,5-bpyridin-7-yl-amine;
6-Bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-1,2,3triazolo4,5bpyridin-7-yl-(1-ethyl-propyl)-methyl-amine;
7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-1,2,3triazolo 4,5-bpyridine;
4-(1 -Ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyi-phenyl)-5H-pyrrolo 3,2-dpyrimidine;
()-2,5-Dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-3,2-dpyrimidine;
2,5-Dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyt-phenyl)-5H-pyrrolo-3,2-dpyrimidine;
2,5-Dimethyl-4-(1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo 3,2-dpyrimidine; or
4-sec-Butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo3,2-dpyrimidine;
or a pharmaceutically acceptable salt of such compound.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A communication device comprising:
a phased array antenna comprising a plurality of antenna elements arranged on a plane configured to receive signals transmitted from one or more transmitting devices;
a signal converter configured to combine signals received through antenna elements for each sub-array and convert the combined signal for each sub-array into a baseband signal, wherein each of the sub-arrays is grouped from the plurality of antenna elements;
a signal processor configured to decode playback data based on respective baseband signals for sub-arrays in each resource block and detect an error of the decoded playback data; and
an orientation controller configured to control orientation of the phased array antenna based on the base band signals for the sub-arrays and a signal of a resource block with the playback data comprising no error.
2. The communication device of claim 1, wherein the orientation controller comprises:
a resource block selector configured to select a resource block with the playback data comprising no error,
a resource block reproducer configured to reproduce a signal of the selected resource block,
a reference signal generator configured to generate a reference signal to be used as a basis in orientation control based on the reproduced signal of the resource block,
a direction error estimator configured to estimate an error in a direction toward the orientation based on the baseband signals of the sub-arrays and the reference signal, and
an orientation setting unit configured to set a direction of orientation of the phased array antenna based on the estimated error.
3. The communication device of claim 2, wherein the resource block selector is configured to select from among resource blocks with the playback data comprising no error, wherein
a resource block comprises a selection of a combination of a high transmission rate of modulation and encoding, wherein the resource block also comprises no second playback data for a second signal transmitted from any other transmitting device than the transmitting device that transmits a first signal that corresponds to the playback data, and wherein the resource block is configured to receive the first signal and the second signal at the same time through the phased array antenna, or
the resource block comprises a selection of a combination of a high transmission rate of modulation and encoding, wherein the resource block comprises second playback data with no error for a second signal transmitted from any other transmitting device simultaneously with a first signal that corresponds to the playback data through the phased array antenna.
4. The communication device of claim 3, wherein the direction error estimator is configured to:
generate a replica interference signal equivalent to an interference signal indicative of interference of a signal transmitted from any other transmitting device with a baseband signal for each of the sub-arrays, based on a channel estimation value from the signal transmitted from the any other transmitting device and based on a signal of a resource block that corresponds to the signal transmitted from the any other transmitting device, and
eliminate components of the replica interference signal from each baseband signal for each sub-array based on the received signal.
5. The communication device of claim 4, wherein the reference signal generator is configured to:
generate a replica baseband signal for each sub-array which is equivalent to a baseband signal for the sub-array, wherein the replica baseband signal for each sub-array is generated based on a signal of a resource block reproduced in the resource block reproducer and based on an estimation value of a re-estimated channel, and wherein the estimation value of the re-estimated channel is based on a baseband signal for each sub-array from which components of the replica interference signal are eliminated and the signal of the resource block, and
combine replica baseband signals for the sub-arrays and generate the reference signal.
6. The communication device of claim 4, wherein the direction error estimator is configured to:
detect a phase error component for each sub-array based on a correlation of a baseband signal for the sub-array from which the replica interference signal is eliminated and the reference signal,
estimate a phase error based on the detected phase error component for the sub-array, and
re-set a direction of an orientation of the phased array antenna based on a direction error between arrival direction of the received signal and a set direction of orientation of the phased array antenna which is converted from the estimated phase error.
7. The communication device of claim 6, wherein the direction error estimator is configured to estimate the phase error using the least squares method.
8. The communication device of claim 5, wherein the direction error estimator is configured to:
detect a phase error component for each sub-array based on a correlation of a baseband signal for the sub-array from which the replica interference signal is eliminated and the reference signal,
estimate a phase error based on the detected phase error component for the sub-array, and
re-set a direction of an orientation of the phased array antenna based on a direction error between arrival direction of the received signal and a set direction of orientation of the phased array antenna which is converted from the estimated phase error.
9. The communication device of claim 1, further comprising a correlator is configured to perform the correlation of the baseband signal for the sub-array from which the replica interference signal is eliminated.
10. The communication device of claim 9, further comprising a phase extractor configured to extract a phase error component for each sub-array based on the correlation.
11. An orientation control method in a communication device that comprises a phased array antenna including a plurality of antenna elements arranged on a plane for receiving signals from one or more transmitting devices, the method comprising:
combining signals received through antenna elements for each sub-array and converting the combined signal for each sub-array into a baseband signal, wherein each of the sub-arrays are grouped from the plurality of antenna elements;
decoding playback data based on respective baseband signals for sub-arrays in each resource block and detecting an error of the decoded playback data; and
controlling orientation of the phased array antenna based on the base band signals for the sub-arrays and a signal of a resource block with the playback data comprising no error.
12. The method of claim 11, further comprising:
selecting, by a resource block selector, a resource block with the playback data comprising no error,
reproducing, by resource block reproducer, a signal of the selected resource block,
generating, by a reference signal generator, a reference signal to be used as a basis in orientation control based on the reproduced signal of the resource block,
estimating, by a direction error estimator, an error in a direction toward the orientation based on the baseband signals of the sub-arrays and the reference signal, and
setting, by an orientation setting unit, a direction of orientation of the phased array antenna based on the estimated error.
13. The method of claim 12, wherein selecting, by the resource block selector comprises selecting from among resource blocks with the playback data comprising no error,
wherein a resource block comprises a selection of a combination of a high transmission rate of modulation and encoding, wherein the resource block also comprises no second playback data for a second signal transmitted from any other transmitting device than the transmitting device that transmits a first signal that corresponds to the playback data, and wherein the resource block receives the first signal and the second signal at the same time through the phased array antenna, or
wherein the resource block comprises a selection of a combination of a high transmission rate of modulation and encoding, wherein the resource block second playback data with no error for a second signal transmitted from any other transmitting device simultaneously with a first signal that corresponds to the playback data through the phased array antenna.
14. The method of claim 13, further comprising:
generating, by the direction error estimator, a replica interference signal equivalent to an interference signal indicative of interference of a signal transmitted from any other transmitting device with a baseband signal for each of the sub-arrays, based on a channel estimation value from the signal transmitted from the any other transmitting device and based on a signal of a resource block that corresponds to the signal transmitted from the any other transmitting device, and
eliminating, by the direction error estimator, components of the replica interference signal from each baseband signal for each sub-array based on the received signal.
15. The method of claim 14, further comprising:
generating, by the reference signal generator, a replica baseband signal for each sub-array which is equivalent to a baseband signal for the sub-array, wherein the replica baseband signal for each sub-array is generated based on a signal of a resource block reproduced in the resource block reproducer and based on an estimation value of a re-estimated channel, and wherein the estimation value of the re-estimated channel is based on a baseband signal for each sub-array from which components of the replica interference signal are eliminated and the signal of the resource block, and
combining, by the reference signal generator, replica baseband signals for the sub-arrays and generating, by the reference signal generator, the reference signal.
16. The method of claim 14, further comprising:
detecting, by the direction error estimator, a phase error component for each sub-array based on a correlation of a baseband signal for the sub-array from which the replica interference signal is eliminated and the reference signal,
estimating, by the direction error estimator, a phase error based on the detected phase error component for the sub-array, and
re-setting, by the direction error estimator, a direction of an orientation of the phased array antenna based on a direction error between arrival direction of the received signal and a set direction of orientation of the phased array antenna which is converted from the estimated phase error.
17. The method of claim 15, further comprising:
detecting, by the direction error estimator, a phase error component for each sub-array based on a correlation of a baseband signal for the sub-array from which the replica interference signal is eliminated and the reference signal,
estimating, by the direction error estimator, a phase error based on the detected phase error component for the sub-array, and
re-setting, by the direction error estimator, a direction of an orientation of the phased array antenna based on a direction error between arrival direction of the received signal and a set direction of orientation of the phased array antenna which is converted from the estimated phase error.
18. The method of claim 17, further comprising, estimating, by the direction error estimator, the phase error using the least squares method.
19. The method of claim 11, further comprising performing, by a correlator, the correlation of the baseband signal for the sub-array from which the replica interference signal is eliminated.
20. The method of claim 19, further comprising, extracting, by a phase extractor, a phase error component for each sub-array based on the correlation.